Amber C. King

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant”.

Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant

Leukemia & lymphoma/Leukemia and lymphoma(2021)10.1080/10428194.2021.1966788

N/A

0.574DataRank · unranked

45 citations

Andriy Derkach, Lohith Gowda, Kamal Menghrajani, Susan DeWolf, Josel D. Ruiz +27 more

Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3815

N/A

0DataRank · unranked

116 citations

Lindsey E. Roeker, Ryan Jacobs, Brian T. Hill, Nicole Lamanna, Danielle M. Brander +49 more

Dermatologic adverse events in acute lymphocytic leukemia patients treated with bispecific T-cell engager blinatumomab

Leukemia & lymphoma/Leukemia and lymphoma(2023)10.1080/10428194.2023.2221756

N/A

0DataRank · unranked

4 citations

Emily A. Cowen, Stephanie Gu, Stephen W. Dusza, Melissa Pulitzer, Mark B. Geyer +3 more